Some 20 weeks after stopping their drugs, the participants in the studies had put back on an average of 2.5 kilograms (5.5 ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

Can it really be maintained after they’re discontinued on top-selling drugs such as Ozempic or Wegovy, or is rebound weight gain simply a natural part of the process? For many adult patients taking ...

Tom Nolan reviews this week’s research Cannabinol—aka CBD—is a modern day tonic for almost any ailment, available in all good vape shops and petrol stations. In 2023, the Food Standards Agency cut the ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...